Tuesday, Johnson & Johnson subsidiary Janssen Biotech entered into a worldwide collaboration and license agreement with Chinese biotech Cellular Biomedicine Group to develop next-generation CAR-T therapies for diffuse large B-cell lymphoma.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,